Curi RMB Capital’s AbbVie ABBV Stock Holding History

Curi RMB Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.7M	Buy	86,122 +2,775	+3%	+$616K	0.33%	79
2025 Q4	$19M	Sell	83,347 -962	-1%	-$219K	0.33%	78
2025 Q3	$19.5M	Buy	84,309 +5,703	+7%	+$1.16M	0.36%	72
2025 Q2	$14.6M	Buy	78,606 +42,455	+117%	+$7.89M	0.28%	102
2025 Q1	$7.57M	Sell	36,151 -14,558	-29%	-$2.83M	0.19%	153
2024 Q4	$9.01M	Sell	50,709 -1,453	-3%	-$267K	0.21%	144
2024 Q3	$10.3M	Buy	52,162 +483	+0.9%	+$90.1K	0.23%	131
2024 Q2	$8.86M	Sell	51,679 -5,054	-9%	-$837K	0.21%	139
2024 Q1	$10.3M	Buy	56,733 +7,175	+14%	+$1.24M	0.24%	126
2023 Q4	$7.68M	Sell	49,558 -924	-2%	-$135K	0.23%	117
2023 Q3	$7.52M	Buy	50,482 +1,495	+3%	+$219K	0.26%	106
2023 Q2	$6.6M	Buy	48,987 +1,319	+3%	+$193K	0.22%	125
2023 Q1	$7.6M	Buy	47,668 +920	+2%	+$141K	0.27%	107
2022 Q4	$7.55M	Buy	46,748 +3,996	+9%	+$613K	0.27%	108
2022 Q3	$5.74M	Sell	42,752 -9,572	-18%	-$1.37M	0.21%	124
2022 Q2	$8.01M	Buy	52,324 +16	+0%	+$2.44K	0.28%	99
2022 Q1	$8.48M	Sell	52,308 -114	-0.2%	-$16.6K	0.27%	102
2021 Q4	$7.1M	Sell	52,422 -3,290	-6%	-$389K	0.21%	110
2021 Q3	$6.01M	Buy	55,712 +1,222	+2%	+$140K	0.2%	116
2021 Q2	$6.14M	Sell	54,490 -75	-0.1%	-$8.45K	0.21%	115
2021 Q1	$5.91M	Sell	54,565 -898	-2%	-$96.1K	0.22%	113
2020 Q4	$5.94M	Sell	55,463 -11,945	-18%	-$1.15M	0.22%	113
2020 Q3	$5.9M	Sell	67,408 -4,064	-6%	-$383K	0.26%	91
2020 Q2	$7.02M	Buy	71,472 +1,037	+1%	+$91.3K	0.31%	82
2020 Q1	$5.37M	Sell	70,435 -384	-0.5%	-$32.7K	0.25%	104
2019 Q4	$6.27M	Sell	70,819 -552	-0.8%	-$45.8K	0.17%	136
2019 Q3	$5.4M	Sell	71,371 -13,796	-16%	-$946K	0.14%	160
2019 Q2	$6.19M	Buy	85,167 +359	+0.4%	+$28.2K	0.16%	157
2019 Q1	$6.83M	Sell	84,808 -1,223	-1%	-$100K	0.17%	145
2018 Q4	$7.93M	Buy	86,031 +6,230	+8%	+$548K	0.2%	130
2018 Q3	$7.55M	Buy	79,801 +331	+0.4%	+$31.4K	0.18%	154
2018 Q2	$7.36M	Sell	79,470 -991	-1%	-$96.8K	0.18%	155
2018 Q1	$7.62M	Sell	80,461 -54,950	-41%	-$6.04M	0.19%	146
2017 Q4	$13.1M	Buy	135,411 +76,696	+131%	+$7.23M	0.34%	76
2017 Q3	$5.22M	Buy	58,715 +18,367	+46%	+$1.4M	0.13%	225
2017 Q2	$2.93M	Buy	40,348 +27,074	+204%	+$1.82M	0.08%	311
2017 Q1	$865K	Buy	13,274 +2,866	+28%	+$180K	0.04%	313
2016 Q4	$652K	Buy	+10,408	New	+$635K	0.04%	279
2016 Q2	–	Sell	-3,662	Closed	-$209K	–	440
2016 Q1	$209K	Sell	3,662 -6,645	-64%	-$370K	0.01%	343
2015 Q4	$611K	Buy	10,307 +582	+6%	+$33.5K	0.03%	279
2015 Q3	$529K	Buy	9,725 +17	+0.2%	+$1.11K	0.04%	317
2015 Q2	$653K	Buy	+9,708	New	+$634K	0.04%	268

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Curi RMB Capital's ABBV Position: Q1 2026 in Review

Curi RMB Capital increased its AbbVie (ABBV) stake by 3.3% in Q1 2026, buying an estimated $616K and bringing the position to 86,122 shares worth $18.7M. The position accounts for 0.33% of the portfolio, ranked #79.

Curi RMB Capital first reported a position in ABBV in Q2 2015 and has held it in 42 quarters since. The position peaked at $19.5M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Curi RMB Capital held 86,122 shares of AbbVie worth $18.7M as of Q1 2026.
Curi RMB Capital bought 2,775 AbbVie shares in Q1 2026, an estimated $616K.
AbbVie made up 0.33% of Curi RMB Capital's portfolio in Q1 2026, its #79 holding.
Curi RMB Capital first reported a position in AbbVie in Q2 2015 and has held it in 42 quarters since.
Curi RMB Capital's AbbVie position peaked at $19.5M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Curi RMB Capital's 13F filing for Q1 2026, filed 15 May 2026.